Truly collaborative in design, the Coriell Personalized Medicine Collaborative® (CPMC®) research study has engaged two independent, expert advisory boards and several partners.
The CPMC Informed Cohort Oversight Board (ICOB) is composed of scientists skilled in genetic research, medical professionals familiar with the use of genetics in medical care, an ethicist and a community leader. This Board evaluates health conditions and genetic variants for inclusion in the CPMC study to determine if the condition is at minimum potentially actionable and to establish the scientific validity of nominated genetic variants as risk factors for the condition.
A second advisory group, the Pharmacogenomics Advisory Group (PAG) is composed of pharmacists, pharmacologists, clinicians with experience in pharmacogenomics, and an ethicist. The PAG reviews medications where efficacy or adverse events are known to be affected by genetic variation and they vote on whether the drug/gene pair is potentially actionable.
The study has come together with renowned centers of medicine and research: the American Pharmacists Association, Boston University Cooper University Hospital, Fox Chase Cancer Center, the Genetics and Public Policy Center, Helix Health of Connecticut, Ohio State University Medical Center, Stanford University, University of Pennsylvania, and Virtua Health.
Informed Cohort Oversight Board (ICOB)
David Pellman, MD
|
Robert C. Green, MD, MPH
|
|
Col (Dr.) Michael Grinkemeyer, USAF, M.C.
|
Jennifer Hoheisel, MS
|
|
Marc Lenburg, PhD
|
Steven Murphy, MD
|
|
Ellis J. Neufeld, MD, PhD
|
Ken Offit, MD, MPH
|
|
Erin O'Shea, PhD
|
Reed Pyeritz, MS, PhD
|
|
|
|
Reverend Floyd White
|
David Pellman, MD, the ICOB Chair, is a Pediatric Oncologist. He is the Ted Williams Senior Investigator at the Dana Farber Cancer Institute and a Professor of Pediatrics at Harvard Medical School. Dr. Pellman is an investigator of the Howard Hughes Medical Institute and an expert in cancer research.
Robert C. Green, MD, MPH is a professor of neurology, genetics, and epidemiology at Harvard Medical School. A physician-researcher, Dr. Green is focused on translational genomics and health outcomes.
Col (Dr.) Michael Grinkemeyer, USAF, M.C. is a molecular genetic pathologist at the United States Air Force School of Aerospace Medicine (USAFSAM), at Wright Patterson AFB. He is board certified in Cytopathology and Anatomic & Clinical Pathology. His experience includes service as the Air Force Deputy Director of the former Armed Forces Institute of Pathology (AFIP), and Lab Director over military hospital laboratories both in the United States and overseas.
Jennifer Hoheisel, MS, is an Associate Professor of Philosophy, the Coordinator of Liberal Arts, and the Honors Program Director at Camden County College. She is also a visiting fellow at Princeton University in the Bioethics and Genomics program.
Marc Lenburg, Ph.D., is an Assistant Professor of Genetics and Genomics at Boston University School of Medicine. He is an expert in biostatistics and bioinformatics and the designer of the GMED (genomic medicine) website for distribution of genetic associations for the Framingham Heart Study.
Steven Murphy, MD, is the Managing Partner and President of The Personalized Medicine Group in New York, NY, and Greenwich, CT. He is a clinical instructor in Cell Biology and Anatomy at New York Medical College and a Yale Affiliated Hospitals speaker. Dr. Murphy is a thought leader in personalized medicine and the author of Gene Sherpas: Personalized Medicine and You, a popular personalized medicine blog.
Ellis J. Neufeld, MD, PhD is presently Associate Chief of the Division of Hematology/Oncology at Children's Hospital, Boston, and Professor of Pediatrics at Harvard Medical School, where he holds the Egan Family Chair in Transitional Medicine.
Ken Offit, MD, MPH, is Chief of Clinical Genetic Services at Memorial Sloan-Kettering and an expert in cancer genetics. His research team identified the most common mutation associated with an increased risk of breast and ovarian cancer among individuals of Ashkenazi Jewish ancestry.
Erin O'Shea, PhD, is the Vice President and Chief Scientific Officer at the Howard Hughes Medical Institute (HHMI) and the past Chair of the ICOB. Dr. O'Shea is also a Professor of Molecular and Cell Biology at Harvard University, a member of the National Academy of Sciences, a HHMI Investigator, and Director of the Faculty of Arts and Sciences Systems Biology Institute at Harvard.
Reed Pyeritz, MS, PhD is Chief, Division of Medical Genetics, University of Pennsylvania School of Medicine and Vice-Chair for Academic Affairs, Department of Medicine, Hospital of the University of Pennsylvania. Dr. Pyeritz focuses his research in two areas: Mendelian disorders of the cardiovascular system, especially those involving defects of connective tissue; and, ethical, legal and social implications of the human genetics.
Charles Rotimi, PhD, is Director of the National Institutes of Health Center for Genomics and Health Disparities. He is President of the African Society of Human Genetics and the Hap Map liasion to the African continent. Dr. Rotimi has a PhD in statistical genetics.
Reverend Floyd White is the Director of the Woodland Community Development Corporation, a non-profit organization that provides employment and educational services to Camden residents. In addition, he serves the Camden, New Jersey community as Pastor of the Woodland Avenue Presbyterian Church. He has been a Camden community leader for over 20 years.Pharmacogenomics Advisory Group (PAG)
Issam Zineh, PharmD, MPH
|
Marialice Bennett, BS, RPh
|
|
Arthur L. Caplan, PhD
|
Michael D. Ezekowitz, MB, ChB, DPhil
|
|
David Flockhart, MD, PhD
|
Andrew K. Godwin, PhD
|
|
Amalia Issa, MPH, PhD
|
Teri E. Klein, PhD
|
|
Calvin H. Knowlton, BSPharm, MDiv, PhD
|
Howard McLeod, PharmD
|
|
Steven Murphy, MD
|
Michael F. Murray, MD
|
|
Michael S. Phillips, PhD
|
Wolfgang Sadee, Dr.rer.nat
|
|
Deepak Voora, MD
|
Issam Zineh, PharmD, MPH, is the PAG chair. Dr. Zineh is Director of the Office of Clinical Pharmacology, Office of Translational Sciences at the FDA, as well as an internationally recognized expert in the field of pharmacogenetics. He is also chair of the Pharmacogenetics and Molecular Pharmacology and Pharmacogenetics Scientific Section of the American Society for Clinical Pharmacology and Therapeutics.
Marialice Bennett, BS, RPh, is a Professor of Clinical Pharmacy at the Ohio State University College of Pharmacy. She also serves as a co-founder and pharmacy director for University Health Connection, an innovative interprofessional healthcare clinic for faculty and staff of the university. Dr. Bennett was elected as the 2010-2011 President-Elect of the American Pharmacist Association.
Arthur L. Caplan, PhD, is currently the Emmanuel and Robert Hart Director of the Center for Bioethics and the Sydney D. Caplan Professor of Bioethics at the University of Pennsylvania in Philadelphia. An expert in the field of Bioethics, he has written or edited twenty-nine books and served on a number of national and international committees. He was described as one of the ten most influential people in science by Discover magazine in 2008.
Michael D. Ezekowitz, MB, ChB, DPhil, is a professor and Vice President of the Lankenau Institute for Medical Research, as well as the Vice President of Clinical Research for Main Line Hospitals. Dr. Ezekowitz is an active non-invasive clinical cardiologist and has been involved in the design and conduct of numerous large clinical trials.
David Flockhart, MD, PhD, is the Chief of the Division of Clinical Pharmacology at the Indiana University School of Medicine where he is also the Director of the Indiana Institute for Personalized Medicine. His research is focused on clinically-relevant applications of pharmacogenetics and drug interactions.
Andrew K. Godwin, PhD, is a Chancellors Distinguished Chair in Biomedical Sciences endowed Professor. He is also Professor in the Department of Pathology & Laboratory Medicine at the University of Kansas Medical Center and their Director of Molecular Oncology. Dr. Godwin plays a role in the University of Kansas Cancer Center as the Associate Director for Translation Research.
Amalia Issa, MPH, PhD, is the Founding Director of the Program in Personalized Medicine and Targeted Therapeutics (P2MT2), as well as an Associate Professor at the College of Pharmacy at the University of Houston. Since 1998, Dr. Issa has developed a unique area of translational research focused on pharmacogenomics and personalized medicine applications, and how they will be translated and integrated into health care delivery and health systems.
Teri E. Klein, PhD, is a senior scientist at Stanford University, where her research interests cover the broad spectrum of pharmacogenetics, computational biology, and bioinformatics. She is also the Director for the PharmGKB (Pharmacogenomics Knowledge Base) and the co-founder and co-chair of the Pacific Symposium on Biocomputing.
Calvin H. Knowlton, BSPharm, MDiv, PhD, is the founder and CEO of RevolutionCare, Inc., a group that provides home-based primary care services, and of CareKinesis, Inc., which provides medication therapy management and pharmacogenomics translation for elderly patients and physicians. Dr. Knowlton has an expansive entrepreneurial career, founding many other successful healthcare companies including excelleRx, a national hospice-focused medication management firm.
Howard McLeod, PharmD, is the Fred Eshelman Distinguished Professor in the Division of Pharmacotherapy and Experimental Therapeutics at the University of North Carolina at Chapel Hill, as well as the director of the UNC Institute for Pharmacogenomics and Individualized Therapy. Dr. McLeod is also the Principal Investigator for CREATE, a member of the NIH-funded Pharmacogenetics Research Network and is a member of the FDA committee on Clinical Pharmacology.
Steven Murphy, MD, is the Managing Partner and President of The Personalized Medicine Group in New York, NY, and Greenwich, CT. He serves on the faculty at New York Medical College as an Instructor in the Department of Cell Biology and Anatomy. Dr. Murphy is a thought leader in personalized medicine and the author of "Gene Sherpas: Personalized Medicine and You," a popular personalized medicine blog.
Michael F. Murray, MD, is Director of the General Genetics Clinic and Clinical Chief of the Genetics Division in the Department of Medicine at Brigham and Women's Hospital. Dr. Murray is also an instructor in medicine at Harvard Medical School. He directs the combined internal medicine-medical genetics residency and runs an annual course on the "genetic and genomic basis of adult medicine".
Michael S. Phillips, PhD, is the recipient of a federal Canada Research Chair in Translational Pharmacogenomics and an Associate Professor in the Faculty of Medicine at the Université de Montréal. He is also the Director the Beaulieu-Saucier Université de Montréal Pharmacogenomics Centre which supports the integration of pharmacogenomics into Clinical Trials and Healthcare.
Wolfgang Sadee, Dr.rer.nat, is the Felts Mercer Professor of Medicine and Pharmacology at Ohio State University Medical Center. He is also the chair of the Department of Pharmacology; a Professor of pharmacy, psychiatry and medical genetics; and the Director of the OSU Program in Pharmacogenomics.
Deepak Voora, MD, is an Associate Investigator for the Duke University Institute for Genome Sciences & Policy. Dr. Voora is also an Instructor of Medicine in the school's Division of Cardiology and his chief research interest is cardiovascular pharmacogenetics.
